ACEA Biosciences Introduces the NovoCyte™ Flow Cytometer

Exceptional Performance at a Low InvestmentUp to Fifteen Parameter Detection with Enhanced Sensitivity and Resolution

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
NovoCyte Flow Cytometer

NovoCyte Flow Cytometer

“With the NovoCyte system, researchers have a new option to advance their studies with the best combination of performance, usability and cost,” said Xiaobo Wang, Ph.D., Chief Technology Officer, ACEA Biosciences

San Diego, CA (PRWEB) April 02, 2014

ACEA Biosciences, a pioneer in the development of high performance cell analysis platforms for life science research known for their xCELLigence® platform, introduces the NovoCyte flow cytometer. The NovoCyte system addresses a full range of multi-parameter cellular analysis research needs with high performance at a low investment cost, making it more attainable for researchers to have benchtop flow cytometers in their labs. The system enables detection of up to fifteen parameters with enhanced sensitivity and resolution and is customizable to meet researchers’ current and future needs with options to add-on at a later date. The NovoCyte flow cytometer is available with one to three laser options, exchangeable filters, multiple sampling options and flexible analysis formats. Operation is intuitive with automated instrument maintenance functions and advanced data analysis capabilities for greater usability. Other important features enhance usability such as a fixed optical alignment, 24-bit detection dynamic range with no need for PMT voltage adjustment, accurate volumetric-based cell counting, pressure sensors to monitor fluidic status in real-time, and automatic cleaning and de-contamination processes.

“Flow cytometry is a powerful tool for cell analysis and yet the cost and complexity of systems can limit accessibility for researchers,” said Xiaobo Wang, Ph.D., Chief Technology Officer, ACEA Biosciences. “With the NovoCyte system, researchers have a new option to advance their studies with the best combination of performance, usability and cost.”

ACEA also developed the NovoExpress™ software which is intuitive and easy to use. Flexible analysis templates and plotting tools offer enhanced data analysis efficiency.

The NovoCyte system will be on display at the ACEA Bioscience booth (#710) at the American Association for Cancer Research (AACR) Annual Meeting 2014 April 5-9, 2014 in San Diego, California.

Media Contact: Reena Patel | Reena.patel at echopublicrelations dot com | O:(919) 381-6702 | M:(919) 744-7556

About ACEA Biosciences
Founded in 2002, ACEA Biosciences, Inc. (ACEA) is a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. Researchers are advancing their studies utilizing 1,000+ placed instruments for broad and diverse applications. The technology has been cited in over 500 peer reviewed publications. ACEA’s xCELLigence® impedance-based, label-free, real time cell system and NovoCyte™ flow cytometers are used in pre-clinical drug discovery and development, toxicity, safety pharmacology, and basic academic research. For more information visit http://www.aceabio.com.


Contact